Skip to main content

Health condition · Clinically reviewed

COPD, inhalers, oxygen and the new biologics that are changing outcomes.

Around three million people in the UK live with COPD, and roughly half do not yet know it. Modern treatment can transform breathlessness, exacerbations and quality of life.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE NG115, GOLD 2024 and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including triple therapy, dupilumab for eosinophilic COPD and endobronchial valves.

Key facts

COPD at a glance.

The essentials, in plain English. What COPD actually is, how common it is in the UK and how modern treatment shifts the trajectory.

  • What it is

    Progressive airflow limitation that is not fully reversible, driven by chronic bronchitis and emphysema phenotypes.

  • How common

    Around 3 million people in the UK are affected, with roughly 1.2 million diagnosed and another 1.8 million undiagnosed.

  • Main cause

    Smoking accounts for more than 80 per cent of UK cases. Occupational dust, fumes and pollution also contribute.

  • Diagnosis

    Post-bronchodilator spirometry confirming a fixed FEV1/FVC ratio below 0.7 in a person with symptoms and risk factors.

  • What changes it

    Stopping smoking is the only intervention proven to slow long-term decline in lung function.

  • Modern therapy

    Inhaled LABA/LAMA and triple therapy, pulmonary rehab, oxygen, non-invasive ventilation and now biologics for selected patients.

Why this guide matters

A ladder that changes outcomes.

COPD is progressive, but it is also one of the most treatable respiratory conditions in the UK when the ladder is followed properly.

  • Stopping smoking is unique

    It is the only intervention that changes the slope of long-term lung function decline. Everything else improves symptoms and exacerbations.

  • Inhalers save admissions

    Correctly chosen LABA/LAMA and triple therapy meaningfully reduce exacerbations. Inhaler technique matters as much as the molecule.

  • The frontier is moving

    Dupilumab, ensifentrine and endobronchial valves have arrived in the last two years and are already reshaping specialist practice.

How the diagnosis is made

From first symptoms to a full plan.

The steps a UK GP and respiratory team will normally follow under NICE NG115 and GOLD, in the order that gets to a treatable diagnosis quickly.

  1. 01

    Assessing

    History and MRC breathlessness

    Chronic cough, sputum, wheeze and progressive breathlessness scored on the mMRC scale 1 to 5, alongside smoking pack-years and occupational exposure.

  2. 02

    Assessing

    CAT and exacerbation history

    The COPD Assessment Test quantifies symptom burden and past exacerbations guide risk stratification and inhaler choice.

  3. 03

    Assessing

    Post-bronchodilator spirometry

    FEV1/FVC below 0.7 with reversibility under 12 per cent confirms fixed airflow obstruction. GOLD stage is then set from FEV1.

  4. 04

    Confirming

    Chest X-ray and HRCT

    Hyperinflation and bullae on plain film. HRCT maps emphysema pattern, screens for bronchiectasis and prepares for lung volume reduction.

  5. 05

    Confirming

    Alpha-1 antitrypsin and bloods

    AAT level once in every person with COPD, plus FBC for polycythaemia and eosinophils to guide inhaled steroid and biologic decisions.

  6. 06

    Confirming

    Gas exchange and heart

    Arterial blood gas for hypoxia and hypercapnia, BNP and echo for cor pulmonale, and a sleep study if overlap with obstructive sleep apnoea is suspected.

  7. 07

    Planning

    Function and MDT plan

    Six-minute walk test, BODE index and a plan built with respiratory nurse, physio and, where relevant, palliative care.

Typical timeline: from first spirometry to a full inhaled plan in weeks, not months.

Symptoms

What COPD actually feels like.

The mix of chronic cough, progressive breathlessness and exacerbations that quietly builds over years, and the features that mean it is time to be seen urgently.

  • Chronic productive cough

    Cough with sputum on most days for three months a year across two consecutive years defines the chronic bronchitis phenotype.

  • Progressive breathlessness

    Dyspnoea that creeps up over years, first on hills and stairs, then on flat ground, scored on the mMRC 1 to 5 scale.

  • Wheeze and chest tightness

    Audible wheeze on exertion and a tight chest, often worse in cold air, smoke or with viral infections.

  • Recurrent chest infections

    More frequent winter bronchitis and pneumonia, with slower recovery between episodes.

  • Exacerbations

    Sustained rise in sputum volume or purulence with worsening breathlessness. Frequent exacerbations drive lung function decline.

  • Weight loss and muscle wasting

    Advanced disease brings systemic effects including sarcopenia, osteoporosis and pulmonary cachexia.

  • Cor pulmonale and oedema

    Right heart strain from chronic hypoxaemia produces raised JVP, ankle swelling and hepatic congestion.

  • Red flag exacerbation

    Confusion, cyanosis, drowsiness or a silent chest need same-day assessment for type II respiratory failure.

Treatment

How COPD is treated in the UK.

Smoking cessation, vaccinations and pulmonary rehab first. Then stepwise inhaled therapy, oxygen, non-invasive ventilation, endobronchial valves and biologics for selected patients.

  • Smoking cessation

    The single most effective intervention. Combine behavioural support with nicotine replacement, varenicline or bupropion, and consider vaping as a harm-reduction tool.

  • Vaccinations

    Annual influenza, one-off pneumococcal, COVID boosters and RSV vaccination in eligible age groups reduce exacerbations and hospital admissions.

  • Pulmonary rehabilitation

    A six to eight week exercise and education programme for anyone at MRC 3 or higher, or after any hospital admission. See our pulmonary rehab guide.

  • LABA plus LAMA inhaler

    Dual bronchodilator therapy (Anoro, Ultibro or Duaklir) for symptomatic patients and those with exacerbations without eosinophilic features.

  • Triple therapy

    LABA, LAMA and inhaled corticosteroid in a single inhaler (Trelegy, Trixeo or Trimbow) for eosinophilic phenotypes and frequent exacerbators.

  • Long-term oxygen therapy

    Oxygen for more than 15 hours a day when resting PaO2 is 7.3 kPa or lower, or 8 kPa with complications, improves survival in chronic hypoxaemia.

  • Non-invasive ventilation

    Domiciliary BiPAP for chronic hypercapnia and NIV in hospital for acute type II respiratory failure. Reduces intubation and mortality.

  • Endobronchial valves and LVR

    Bronchoscopic valves (Zephyr or Spiration) or surgical lung volume reduction for selected emphysema with heterogeneous disease and hyperinflation.

  • Mucolytics

    Carbocisteine or N-acetylcysteine can reduce sputum viscosity and exacerbation frequency in a subset of chronic bronchitis patients.

  • Biologics and ensifentrine

    Dupilumab is the first biologic approved for type 2 eosinophilic COPD with frequent exacerbations. Ensifentrine (Ohtuvayre), a first-in-class PDE3 and PDE4 inhibitor, is an emerging option.

  • Exacerbation treatment

    Bronchodilators, oral prednisolone 30 mg for five days, targeted antibiotics, controlled oxygen and NIV or admission when indicated.

  • Alpha-1 augmentation

    Specialist intravenous alpha-1 antitrypsin (Prolastin) for selected patients with genetically confirmed deficiency and early-onset emphysema.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, GOLD strategy and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or respiratory team knows your lungs and history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115).

  • GOLD. Global Strategy for Prevention, Diagnosis and Management of COPD, 2024 report.

  • British Thoracic Society. Guidelines on home oxygen, non-invasive ventilation and pulmonary rehabilitation.

  • MHRA and NICE technology appraisals on triple therapy, dupilumab and ensifentrine for COPD.

  • Asthma and Lung UK. Patient information and support resources for people living with COPD.

Red flags

When COPD needs urgent attention.

Most COPD is managed in primary care with respiratory nurse support. These are the situations that need same-day or specialist input.

  • Type II respiratory failure

    Rising CO2 with drowsiness, flap or confusion needs urgent hospital assessment for controlled oxygen and non-invasive ventilation.

  • Severe exacerbation

    Marked breathlessness, cyanosis, inability to speak in full sentences or a silent chest is a medical emergency.

  • New haemoptysis

    Coughing up blood in a smoker with COPD needs an urgent two-week wait chest X-ray and CT to exclude lung cancer.

  • Sudden pleuritic chest pain

    Consider pneumothorax, especially in tall thin smokers or those with bullous emphysema. Also consider pulmonary embolism.

  • Cor pulmonale

    Progressive ankle oedema and raised JVP point to right heart failure and warrant echo, diuretics and oxygen assessment.

  • Alpha-1 antitrypsin deficiency

    Early-onset COPD before age 45, minimal smoking history or a family history should trigger AAT testing and specialist referral.

  • Unintentional weight loss

    Rapid weight loss or cachexia flags advanced disease, occult malignancy or the need for palliative and nutritional input.

  • Overlap with obstructive sleep apnoea

    Loud snoring, witnessed apnoeas and daytime sleepiness in COPD (overlap syndrome) needs a sleep study and often overnight NIV.

  • Frequent hospital admissions

    Two or more admissions a year should prompt escalation to triple therapy, biologics assessment and review by a respiratory specialist.

Living with it

A progressive condition, with a strong plan.

Four things that make the biggest difference day to day. Stopping smoking, staying active, having a rescue plan and asking for help early.

A quiet reminder

Consistency beats intensity, every time.

Small, steady habits, kept up for months, protect your lungs and your independence far more than any one big push.

  1. 01 Stop

    Stop smoking, keep stopping

    Every attempt counts. Combining behavioural support with NRT, varenicline or bupropion roughly triples the chance of quitting for good.

  2. 02 Move

    Keep moving every day

    Daily walking, pulmonary rehab and simple resistance work protect muscle mass, mood and breathlessness scores.

  3. 03 Plan

    Have a rescue plan

    A written self-management plan with rescue steroids and antibiotics for exacerbations shortens episodes and reduces admissions.

  4. 04 Support

    Ask for help early

    Respiratory nurses, physios, oxygen teams and Asthma and Lung UK exist for a reason. Reach out before things get frightening.

Frequently asked

Everything we get asked about COPD.

Quick answers on inhalers, oxygen, non-invasive ventilation and the new wave of biologics.

  • What is COPD?

    Chronic obstructive pulmonary disease is a progressive lung condition with airflow limitation that is not fully reversible. It combines the chronic bronchitis and emphysema phenotypes and is confirmed by post-bronchodilator spirometry showing a fixed FEV1/FVC ratio below 0.7 in a symptomatic person with risk factors.

  • Is COPD only caused by smoking?

    Smoking causes more than 80 per cent of UK cases, but not all. Occupational dust and fumes, biomass and outdoor pollution, childhood respiratory infections, prematurity, cannabis smoke, post-tuberculosis damage, HIV and alpha-1 antitrypsin deficiency all contribute. A significant minority of people with COPD have never smoked.

  • Can COPD be reversed?

    No. Airflow limitation in COPD is not fully reversible. However, stopping smoking is the only intervention proven to slow long-term decline in lung function, and modern inhalers, pulmonary rehabilitation, oxygen and non-invasive ventilation can dramatically improve symptoms, exacerbations and quality of life.

  • What is triple therapy and who needs it?

    Triple therapy combines a long-acting beta agonist, a long-acting muscarinic antagonist and an inhaled corticosteroid in one inhaler such as Trelegy, Trixeo or Trimbow. NICE and GOLD reserve it for people with frequent exacerbations, especially those with a blood eosinophil count of 300 cells per microlitre or higher.

  • What about biologics like dupilumab?

    Dupilumab is the first biologic approved for type 2 eosinophilic COPD with frequent exacerbations, based on the BOREAS and NOTUS trials. Ensifentrine, a first-in-class PDE3 and PDE4 inhibitor, is another 2024 addition. Access and NICE approval in the UK are evolving and both are specialist decisions.

  • When should I ask for pulmonary rehab or oxygen?

    Ask about pulmonary rehab at MRC breathlessness grade 3 or higher, or after any hospital admission. Long-term oxygen therapy is considered when resting PaO2 is 7.3 kPa or lower, or 8 kPa with complications like cor pulmonale or polycythaemia. Both need a formal respiratory assessment.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.